Company Filing History:
2 out of 832,843 Years Active: 2011-2012
Title: Marco Mosca: Innovator in Pharmaceutical Chemistry
Introduction
Marco Mosca is a notable inventor based in L'Aquila, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target neutrophil activation.
Latest Patents
Marco Mosca holds 2 patents related to 2-phenylpropionic acid derivatives and their pharmaceutical compositions. These compounds are designed to inhibit the chemotactic activation of neutrophils induced by the interaction of Interleukin-8 with CXCR1 and CXCR2 membrane receptors. The applications of these compounds are crucial for the prevention and treatment of various pathologies, including psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, and glomerulonephritis. Notably, these metabolites do not exhibit cyclo-oxygenase inhibition activity, making them particularly useful in treating neutrophil-dependent pathologies and in preventing damage caused by ischemia and reperfusion.
Career Highlights
Throughout his career, Marco Mosca has focused on innovative solutions in pharmaceutical chemistry. His work has led to advancements that have the potential to improve treatment options for patients suffering from various inflammatory conditions.
Collaborations
Marco has collaborated with esteemed colleagues, including Marcello Allegretti and Riccardo Bertini, to further enhance the impact of his research and innovations.
Conclusion
Marco Mosca's contributions to pharmaceutical chemistry exemplify the importance of innovation in developing effective treatments for complex medical conditions. His work continues to pave the way for advancements in the field.